[Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc. (MAZE), reported the grant of 40,000 restricted stock units (RSUs) on 09/22/2025. Each RSU represents a contingent right to one share of common stock upon settlement. The award vests in two equal installments: 20,000 RSUs vest on September 1, 2026 and 20,000 RSUs vest on September 1, 2027, subject to continued service. The RSUs have no exercise price and do not expire; they either vest or are cancelled prior to vesting. The reported ownership following the grant is 40,000 shares held directly. The Form 4 was signed by an attorney-in-fact on 09/24/2025.

Positive

• 40,000 RSUs granted to the President, R&D & CMO which aligns executive incentives with shareholder outcomes
• Clear two‑step vesting schedule (50% on 09/01/2026 and 50% on 09/01/2027) encourages retention over multiple years
• RSUs have no exercise price and do not expire, simplifying settlement mechanics to one share per unit

Negative

• None.

Insights

Compensation & Governance Analyst

TL;DR: A standard time‑based equity grant of 40,000 RSUs aligns the executive with long‑term shareholder value via multi‑year vesting.

The grant is a routine, time‑based restricted stock unit award with 50% vesting after one year and the remainder after two years, subject to continued service. The award has a $0 settlement price and no expiration, indicating settlement in shares rather than an option exercise. For governance review, the award size should be compared to company peer practices and the executive's total compensation to assess dilution and retention impact; such comparative data is not provided in this filing.

Securities Compliance Specialist

TL;DR: Form 4 correctly discloses the grant date, amount, vesting schedule, and direct ownership following issuance.

The filing includes the required elements: reporting person identity and role, transaction date, security type, number of RSUs granted, vesting schedule, and direct ownership after the transaction. The signature by an attorney‑in‑fact is dated two days after the transaction date, consistent with timely reporting obligations. No information in the filing suggests a reporting or procedural irregularity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Bernstein Harold

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D & CMO

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	09/22/2025		A		40,000		(2)	(3)	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

2. The award shall vest as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date.

3. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Harold Bernstein report on the Form 4 for MAZE?

The Form 4 reports a grant of 40,000 restricted stock units (RSUs) awarded on 09/22/2025, with the reporter holding 40,000 shares directly following the grant.

When do the RSUs awarded to MAZE's President vest?

The award vests in two equal installments: 20,000 RSUs on September 1, 2026 and 20,000 RSUs on September 1, 2027, subject to continued service.

Do the RSUs granted to Harold Bernstein have an exercise price or expiration?

No. The RSUs have a $0 price and are described as not expiring; they either vest or are cancelled prior to vesting.

How was the Form 4 signed and when?

The Form 4 includes a signature by Courtney Phillips, as attorney‑in‑fact, dated 09/24/2025.

Is the reported ownership direct or indirect?

The filing indicates direct ownership (D) of the 40,000 RSUs following the reported transaction.